Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis

Detalles Bibliográficos
Autores principales: Mastorino, Luca, Siliquini, Niccolò, Avallone, Gianluca, Ortoncelli, Michela, Quaglino, Pietro, Dapavo, Paolo, Ribero, Simone
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PAGEPress Publications, Pavia, Italy 2022
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527684/
https://www.ncbi.nlm.nih.gov/pubmed/36199899
http://dx.doi.org/10.4081/dr.2022.9282
_version_ 1784801126959284224
author Mastorino, Luca
Siliquini, Niccolò
Avallone, Gianluca
Ortoncelli, Michela
Quaglino, Pietro
Dapavo, Paolo
Ribero, Simone
author_facet Mastorino, Luca
Siliquini, Niccolò
Avallone, Gianluca
Ortoncelli, Michela
Quaglino, Pietro
Dapavo, Paolo
Ribero, Simone
author_sort Mastorino, Luca
collection PubMed
description
format Online
Article
Text
id pubmed-9527684
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher PAGEPress Publications, Pavia, Italy
record_format MEDLINE/PubMed
spelling pubmed-95276842022-10-04 Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis Mastorino, Luca Siliquini, Niccolò Avallone, Gianluca Ortoncelli, Michela Quaglino, Pietro Dapavo, Paolo Ribero, Simone Dermatol Reports Letter PAGEPress Publications, Pavia, Italy 2022-03-17 /pmc/articles/PMC9527684/ /pubmed/36199899 http://dx.doi.org/10.4081/dr.2022.9282 Text en ©Copyright: the Author(s) https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Letter
Mastorino, Luca
Siliquini, Niccolò
Avallone, Gianluca
Ortoncelli, Michela
Quaglino, Pietro
Dapavo, Paolo
Ribero, Simone
Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis
title Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis
title_full Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis
title_fullStr Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis
title_full_unstemmed Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis
title_short Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis
title_sort seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis
topic Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527684/
https://www.ncbi.nlm.nih.gov/pubmed/36199899
http://dx.doi.org/10.4081/dr.2022.9282
work_keys_str_mv AT mastorinoluca sevencancerpatientsreceivingguselkumabfortreatmentofmoderatetoseverepsoriasis
AT siliquininiccolo sevencancerpatientsreceivingguselkumabfortreatmentofmoderatetoseverepsoriasis
AT avallonegianluca sevencancerpatientsreceivingguselkumabfortreatmentofmoderatetoseverepsoriasis
AT ortoncellimichela sevencancerpatientsreceivingguselkumabfortreatmentofmoderatetoseverepsoriasis
AT quaglinopietro sevencancerpatientsreceivingguselkumabfortreatmentofmoderatetoseverepsoriasis
AT dapavopaolo sevencancerpatientsreceivingguselkumabfortreatmentofmoderatetoseverepsoriasis
AT riberosimone sevencancerpatientsreceivingguselkumabfortreatmentofmoderatetoseverepsoriasis

Ejemplares similares